Reduction in Patient-reported Acute Morbidity in Prostate Cancer Patients Treated With 81-Gy Intensity-modulated Radiotherapy Using Reduced Planning Target Volume Margins and Electromagnetic Tracking: Assessing the Impact of Margin Reduction Study

Urology

Volumn 75, Issue 5, 2010, Pages 1004-1008

  Sandler, Howard M ^a   Liu, Ping Yu ^b   Dunn, Rodney L ^c   Khan, David C ^d   Tropper, Scott E ^d   Sanda, Martin G ^e   Mantz, Constantine A ^d  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d 21ST CENTURY ONCOLOGY   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; ELECTROMAGNETIC RADIATION; EXTERNAL BEAM RADIOTHERAPY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; QUALITY OF LIFE; QUESTIONNAIRE; RADIATION DETECTION; SELF REPORT; THERAPY EFFECT; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ELECTROMAGNETIC PHENOMENA; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 77951665730     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.10.072     Document Type: Article

References (15)

1. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs. high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate. JAMA 294 (2005) 1233-1239
2. Kuban D.A., Tucker S.L., Dong L., et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70 (2008) 67-74
3. Peeters S.T., Heemsbergan W.D., Koper P.C., et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24 (2006) 1990-1996
4. Dearnaley D.P., Sydes M.R., Graham J.D., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomized controlled trial. Lancet Oncol 8 (2007) 475-487
5. Gauthier I., Carrier J.F., Béliveau-Nadeau D., et al. Dosimetric impact and theoretical clinical benefits of fiducial markers for dose escalated prostate cancer radiation treatment. Int J Radiat Oncol Biol Phys 74 (2009) 1128-1133
6. Huang S.H., Catton C., Jezioranski J., et al. The effect of changing technique, dose, and PTV margin on therapeutic ratio during prostate radiotherapy. Int J Radiat Oncol Biol Phys 71 (2008) 1057-1064
7. Wei J.T., Dunn R.L., Litwin M.S., et al. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 56 (2000) 899-905
8. Kupelian P., Willoughby T., Mahadevan A., et al. Multi-institutional clinical experience with the Calypso system in localization and continuous, real-time monitoring of the prostate gland during external radiotherapy. Int J Radiat Oncol Biol Phys 67 (2007) 1088-1098
9. Sanda M.G., Dunn R.L., Michalski J., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358 (2008) 1250-1261
10. Scoring instructions for the expanded prostate cancer index composite (EPIC): University of Michigan. http://roadrunner.cancer.med.umich.edu/epic/EPIC-Scoring-2.2002.pdf Accessed August 12, 2009
11. Norman G.R., Sloan J.A., and Wyrwich K.W. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 41 (2003) 582-592
12. Litzenberg D.W., Balter J.M., Hadley S.W., et al. Influence of intrafraction motion on margins for prostate radiotherapy. Int J Radiat Oncol Biol Phys 65 (2006) 548-553
13. Dearnaley D.P., Khoo V.S., Norman A.R., et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 353 (1999) 267-272
14. Heemsbergen W.D., Peeters S.T., Koper P.C., et al. Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. Int J Radiat Oncol Biol Phys 66 (2006) 3-10
15. Zelefsky M.J., Levin E.J., Hunt M., et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 70 (2008) 1124-1129